Cargando…
Imatinib Mesylate for the Treatment of Canine Mast Cell Tumors: Assessment of the Response and Adverse Events in Comparison with the Conventional Therapy with Vinblastine and Prednisone
Mast cell tumors (MCTs) are common neoplasms in dogs, and treatments for these diseases include surgery, polychemotherapy and targeted therapy with tyrosine kinase inhibitors. This study aimed to evaluate the response and the adverse events of treatment with imatinib mesylate (IM) compared to conven...
Autores principales: | Macedo, Thais Rodrigues, de Queiroz, Genilson Fernandes, Casagrande, Thaís Andrade Costa, Alexandre, Pâmela Almeida, Brandão, Paulo Eduardo, Fukumasu, Heidge, Melo, Samanta Rios, Dagli, Maria Lucia Zaidan, Pinto, Ana Carolina B. C. Fonseca, Matera, Julia Maria |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8834544/ https://www.ncbi.nlm.nih.gov/pubmed/35159380 http://dx.doi.org/10.3390/cells11030571 |
Ejemplares similares
-
Evaluation of prognostic markers for canine mast cell tumors treated with vinblastine and prednisone
por: Webster, Joshua D, et al.
Publicado: (2008) -
c‐Kit Mutation and Localization Status as Response Predictors in Mast Cell Tumors in Dogs Treated with Prednisone and Toceranib or Vinblastine
por: Weishaar, K.M., et al.
Publicado: (2017) -
Successful Long-Term Control of the Syndrome of Episodic Angioedema With Eosinophilia (Gleich Syndrome) With Low-Dose Imatinib Mesylate and Prednisone
por: Butterfield, Joseph H.
Publicado: (2021) -
Periorbital edema secondary to imatinib mesylate
por: McClelland, Collin M, et al.
Publicado: (2010) -
Cutaneous adverse effects of imatinib mesylate
por: Dogu, Mehmet Hilmi, et al.
Publicado: (2015)